Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,258 signal articles · 45 in last 24h · 115,255 total before filter · latest 1h ago
45last 24h
1803last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
AllMacro322Earnings851M&A104Regulatory25Product16Analyst25
✕ clear all filtersticker: MRKSentiment:bullishneutralbearishshow all (incl. clickbait)
Big Tech stocks tumble while Micron continues to gain on Q3 earnings
Yahoo Finance Video51d agobearishVIDEO
Big Tech stocks tumble while Micron continues to gain on Q3 earnings

US stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).

Merck KGaA Q1 Earnings Call Highlights
MarketBeat94d agoneutral
Merck KGaA Q1 Earnings Call Highlights

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

Germany’s Merck KGaA Raises Guidance
The Wall Street Journal94d agobullish
Germany’s Merck KGaA Raises Guidance

The outlook lift comes on expectations of stronger momentum in the group’s life-sciences unit, resilience in healthcare, as well as its first-quarter performance and market conditions.

Codexis Q1 Earnings Call Highlights
MarketBeat100d agoneutral
Codexis Q1 Earnings Call Highlights

Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million